RenovoRx (RNXT) News Today $1.00 +0.01 (+0.61%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical TrialApril 1 at 8:30 AM | businesswire.comHC Wainwright Weighs in on RenovoRx FY2024 EarningsApril 1 at 1:17 AM | americanbankingnews.comHC Wainwright Initiates Coverage on RenovoRx (NASDAQ:RNXT)March 29 at 2:07 AM | americanbankingnews.comRenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual MeetingMarch 28, 2025 | businesswire.comHC Wainwright & Co. Initiates Coverage of RenovoRx (RNXT) with Buy RecommendationMarch 28, 2025 | msn.comRenovoRx honorée pour sa recherche sur le traitement du cancerMarch 27, 2025 | fr.investing.comRenovoRx (NASDAQ:RNXT) Stock Price Up 11.5% - Still a Buy?March 25, 2025 | americanbankingnews.comRenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer ReordersFebruary 27, 2025 | finance.yahoo.comRenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer ReordersFebruary 26, 2025 | businesswire.comRenovoRx presents data from Trans-Arterial Micro-Perfusion therapy platformFebruary 13, 2025 | markets.businessinsider.comRenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common StockFebruary 12, 2025 | finance.yahoo.comRenovoRx 11.52M share Spot Secondary priced at $1.05February 7, 2025 | msn.comRenovoRx Announces Pricing Of Public Offering Of About 11.52 Million Shares At $1.05/shrFebruary 7, 2025 | markets.businessinsider.comRenovoRx lance une offre publique d'actionsFebruary 6, 2025 | fr.investing.comRenovoRx launches public stock offeringFebruary 6, 2025 | msn.comRenovoRx announces common stock offering, no amount givenFebruary 6, 2025 | markets.businessinsider.comRenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common StockFebruary 6, 2025 | businesswire.comRenovoRx Announces Proposed Public OfferingFebruary 6, 2025 | finance.yahoo.comRenovoRx Announces Proposed Public OfferingFebruary 6, 2025 | businesswire.comRenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant DiscountFebruary 5, 2025 | seekingalpha.comAnalysts Expect Breakeven For RenovoRx, Inc. (NASDAQ:RNXT) Before LongJanuary 23, 2025 | finance.yahoo.comRenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy PlatformDecember 30, 2024 | finance.yahoo.comRenovoRx announces SCRI Oncology partners enrolling patients for trialDecember 11, 2024 | markets.businessinsider.comRenovoRx receives first purchase orders for FDA-cleared RenovoCathDecember 6, 2024 | markets.businessinsider.comRenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery SystemDecember 5, 2024 | finance.yahoo.comNorthwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical TrialNovember 21, 2024 | markets.businessinsider.comRenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trialNovember 21, 2024 | markets.businessinsider.comNorthwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical TrialNovember 20, 2024 | globenewswire.comPositive Outlook for RenovoRx: Promising TIGeR-PaC Phase 3 Trial Results and Innovative Drug Delivery Platform Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comRenovoRx Reports Third Quarter 2024 Financial Results and Operational HighlightsNovember 14, 2024 | globenewswire.comWe Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth CarefullySeptember 26, 2024 | finance.yahoo.comRenovoRx augmente la production de son système RenovoCathSeptember 25, 2024 | fr.investing.comRenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology PhysiciansSeptember 25, 2024 | globenewswire.comRenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic CancerSeptember 19, 2024 | globenewswire.comRenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New YorkAugust 27, 2024 | globenewswire.comBuy Rating Backed by RenovoRx’s Clinical Advancements and Sustained Financial HealthAugust 16, 2024 | markets.businessinsider.comRenovoRx continues drug-device combo Phase III trial in pancreatic cancerAugust 15, 2024 | finance.yahoo.comRenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical TrialAugust 14, 2024 | globenewswire.comRNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024August 13, 2024 | investorplace.comLa thérapie TAMP est prometteuse pour la survie des patients atteints de cancer du pancréasJuly 31, 2024 | fr.investing.comRenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®July 31, 2024 | markets.businessinsider.comRenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®July 8, 2024 | globenewswire.comRenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®July 8, 2024 | globenewswire.comUniversity of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical TrialJune 26, 2024 | globenewswire.comRenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and PartnershipsJune 10, 2024 | globenewswire.comRenovoRx CEO Issues Update Letter to ShareholdersMay 30, 2024 | businesswire.comPublication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment DeliveryMay 21, 2024 | finance.yahoo.comPublication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment DeliveryMay 21, 2024 | businesswire.comRenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024May 14, 2024 | finance.yahoo.comRNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024May 13, 2024 | investorplace.com Remove Ads Get RenovoRx News Delivered to You Automatically Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter. Email Address RNXT Media Mentions By Week RNXT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNXT News Sentiment▼0.640.78▲Average Medical News Sentiment RNXT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNXT Articles This Week▼111▲RNXT Articles Average Week Remove Ads Get RenovoRx News Delivered to You Automatically Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BMEA News BDTX News JAGX News PLRX News VTYX News ARTV News CRBU News IFRX News ATOS News ORMP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNXT) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNXT Stock Free RNXT Stock Alerts